Cancer CLINICAL TRIALS AND RESEARCH
Renown Institute for Cancer, in collaboration with the National Cancer Institute and the Nevada Cancer Research Foundation, offers over 40 clinical trials for a variety of cancers. Participating in clinical trials and research allows you to receive the most effective therapy available. These treatments investigate promising new drugs, drug combinations, advances in personalized care and new approaches to surgery or radiation therapy that are otherwise unavailable in traditional treatment.
If you are considering a clinical trial, talk to a member of your cancer care team and consult with your doctor. We are here to provide education and guidance in making decisions about your care and treatment. Our specially trained research nurses will help you understand the process and explain what to expect with each visit. We are committed to bringing the highest quality of cancer care to you and your loved ones.
Cancer GENETICS PROGRAM
The Genetic Risk Assessment program works with patients whose personal medical and family history indicates a possible hereditary cancer syndrome. In hereditary cancer, gene mutations can be passed on from generation to generation.
This program has seen more than 2,400 patients since its inception. The majority of patients undergo genetic studies based on comprehensive personal and family history analysis. All results are then reviewed with you and your provider for management decisions. By making genetic testing choices available based on pertinent clinical history, our program can achieve meaningful results and reduce the cost of healthcare.
The program has implemented cancer genetic clinical research protocols, establishing a presence on the regional Institutional Review Board( IRB).
Community outreach includes presentations at local tumor boards and lecture series for clinicians, students and administration. Standardizing genetic information into electronic medical records is also underway. Regional implementation of current National Comprehensive Cancer Network( NCCN) guidelines is the goal.
R. Nathan Slotnick, MD, PhD Medical Director of Genetics
10